Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(04): 231-235
DOI: 10.4103/sajc.sajc_198_17
ORIGINAL ARTICLE: Gynaecologic Cancers

Treatment of locally advanced carcinoma cervix with special emphasis on brachytherapy: A practice pattern survey among young radiation oncologist of India

Anis Bandyopadhyay
Department of Radiotherapy, Medical College Kolkata, Kolkata, West Bengal
,
Poulami Basu
Department of Radiotherapy, Medical College Kolkata, Kolkata, West Bengal
,
Kaushik Roy
Department of Radiotherapy, Medical College Kolkata, Kolkata, West Bengal
,
Suman Das
Department of Radiations Oncology, Queen's NRI Hospital, Vishakapatnam, Andhra Pradesh
,
Susovan Banerjee
Department of Radiation Oncology, Medanta The Medicity, Gurgaon, Haryana
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: Carcinoma cervix is one of the two most common cancers of Indian women with very high morbidity and mortality burden. Although India probably is the leading country in numbers patients of cervix treated radically with combination of teletherapy and brachytherapy (BT), there is presumed diversity of practice across the country due to the inequality of available infrastructure, absence of uniform the training of the radiation oncologists, and absence of any national guidelines. The present survey was conducted to determine current practice patterns in management of locally advanced carcinoma cervix with regard to gynecologic high-dose-rate among the radiation oncologist across the country. Methodology: A 25-item survey was undertaken to study the standard management pattern of Stage IIB–IIIB cervical cancer with special emphasis on the BT practice patterns among various young radiation oncologist working across the country. The survey was undertaken in person in the form of interview questionnaire among the younger members of association of radiation oncologist of India during two national conferences, along with telephonic interview of other members as obtained from the national directory. Results: About 57 young radiation oncologists from 57 centers across the country were surveyed. 25 of them represented private nonacademic centers, 24 represented government academic centers, the rest were from private academic, nongovernmental organization (NGO) run and other centers. The most common teletherapy dose prescribed was 46 Gy/23# for Stage II, and50 Gy/25 # for Stage III disease. HDR after loader with 192Ir is the most common machine (82.6%) in use and computed tomography scan is the most commonly (30/57) used imaging for planning. The most common intracavitary dose pattern for all stages was 7 Gy × 3 fractions (30/57s) and 9 Gy × 2 (12/57) fractions. Although in most centers, computed tomography-based delineation of organs at risk is done routinely; however, target volume delineation and dose prescription/optimization for the same is routinely done in handful of centers (5/57). The mean planned dose to Point A for combined external-beam radiation and BT (EQD210) wasabout 77.5 Gy for Stage IIIB and 72.6 Gy for Stage II disease. Conclusion: Although fractionation patterns may vary, the overall mean dose administered for cervical cancer is similar across the country, which is slightly lower than the recommended doses as per stage by various international guidelines.

Key words

Brachytherapy - carcinoma cervix - India - practice pattern


Publication History

Article published online:
21 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Shrivastava S, Mahantshetty U, Engineer R, Tongaonkar H, Kulkarni J, Dinshaw K, et al. Treatment and outcome in cancer cervix patients treated between 1979 and 1994: A single institutional experience. J Cancer Res Ther 2013;9:672-9.
  • 2 Ferlay JS, Evrik I, Forman M, Bray FD. Cancer Incidence and Mortality Worldwide 2013: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2012.
  • 3 Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer cervix in India. Indian J Med Res 2009;130:219-21.
  • 4 Lanciano RM, Won M, Coia LR, Hanks GE. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys 1991;20:667-76.
  • 5 Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE, Ling CC, et al. Carcinoma of the cervix: Patterns of care studies: Review of 1978, 1983, and 1988-1989 surveys. Int J Radiat Oncol Biol Phys 1995;32:1481-6.
  • 6 Saibishkumar EP, Patel FD, Sharma SC. Evaluation of late toxicities of patients with carcinoma of the cervix treated with radical radiotherapy: An audit from India. Clin Oncol (R Coll Radiol) 2006;18:30-7.
  • 7 Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;48:201-11.
  • 8 Foroudi F, Bull CA, Gebski V. Radiation therapy for cervix carcinoma: Benefits of individualized dosimetry. Clin Oncol (R Coll Radiol) 2002;14:43-9.
  • 9 Sundar S, Symonds P, Deehan C. Tolerance of pelvic organs to radiation treatment for carcinoma of cervix. Clin Oncol (R Coll Radiol) 2003;15:240-7.
  • 10 Forrest JL, Ackerman I, Barbera L, Barnes EA, Davidson M, Kiss A, et al. Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix. Int J Gynecol Cancer 2010;20:1074-8.
  • 11 Stewart AJ, Viswanathan AN. Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer. Cancer 2006;107:908-15.
  • 12 Simmor T, Conibear J, Diez P, Miles E, McCormack M. A Survey of UK Practice in Cervical Cancer Radiotherapy aimed at Developing Trial Specific Quality Assurance. PD-0266. 2nd ed. Geneva: Estro Forum; 2013. p. S104.
  • 13 Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD. Low dose rate vs. High dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: A clinical trial. Int J Radiat Oncol Biol Phys 1994;28:335-41.
  • 14 Fu KK, Phillips TL. High-dose-rate versus low-dose-rate intracavitary brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1990;19:791-6.
  • 15 Hareyama M, Sakata K, Oouchi A, Nagakura H, Shido M, Someya M, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: A randomized trial. Cancer 2002;94:117-24.
  • 16 Inoue T. The trail of the development of high-dose-rate brachytherapy for cervical cancer in Japan. Jpn J Clin Oncol 2003;33:327-30.
  • 17 Teshima T, Inoue T, Ikeda H, Miyata Y, Nishiyama K, Inoue T, et al. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer 1993;72:2409-14.
  • 18 Wang X, Liu R, Ma B, Yang K, Tian J, Jiang L, et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 2010;(7):CD007563.
  • 19 Petereit DG, Sarkaria JN, Potter DM, Schink JC. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: Analysis of tumor recurrence – The university of Wisconsin experience. Int J Radiat Oncol Biol Phys 1999;45:1267-74.
  • 20 Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, Khorprasert C, Rojpornpradit P, Chottetanaprasith T, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 2004;59:1424-31.
  • 21 Banerjee S, Mahantshetty U, Shrivastava S. Brachytherapy in India – A long road ahead. J Contemp Brachytherapy 2014;6:331-5.
  • 22 Eifel P. Patterns of radiotherapy practice for patients treated for intact cervical cancer in 2005-2007: A QRRO study. Int J Radiat Biol Phys 2010;78:S119.
  • 23 Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: A survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2010;76:104-9.